|
88%
agree
9 votes
|
Zetia and Vytorin are hugely successful cholesterol drugs |
|
50%
agree
2 votes
|
Schering-Plough working with JNJ on successor to Remicade |
|
80%
agree
5 votes
|
Organon was expensive acquisition for Schering-Plough |
|
25%
agree
4 votes
|
Pipeline does not have a strong outlook |
|
25%
agree
4 votes
|
Recent challenges to Zetia would be a huge blow |
May 25, 2013
Schering-Plough (NYSE: SGP) is one of the medium-sized players in the pharmaceutical industry, with sales of $18.5 billion in 2008. Its two largest products are autoimmune medication Remicade, sold internationally, and Zetia & Vytorin, a joint venture taken with Merck (MRK) that fights cholesterol. While growth of Remicade has been strong, Vytorin has taken a hit after studies questioned its efficacy compared to the older drug it is based on and in treating blockage of the heart valve.[1]
Like most companies in the industry, Schering-Plough faces challenges to developing new medications, patent expiration, federal regulation, and changes to insurance plans. Schering-Plough has a particularly small pipeline, with very few drugs currently in development. In the near term, it does however have one of the safest profiles in the industry, with very few major patents coming up for expiration in the coming years.
(Read more at Wikinvest
) - Corporate Overview
- Business Growth
- Products and Revenue
- Pharmaceuticals ($10.2 Billion)
- Cholesterol Joint Venture ($5.2 Billion)
- Consumer Health Care ($1.3 Billion)
- Animal Health ($1.3 Billion)
- Organon Acquisition
- Trends and Forces
- Research and Development
- Patent expirations
- Politics and Insurance
- Comparison to Competitors
- References
